# Efficacy and Safety of Bevacizumab (Avastin®) Combined to Weekly Paclitaxel Followed by Bevacizumab (Avastin®) Alone in Patients With Relapsed Ovarian Sex-cord Stromal Tumours (ALIENOR)

> **NCT01770301** · PHASE2 · COMPLETED · sponsor: **ARCAGY/ GINECO GROUP** · enrollment: 60 (actual)

## Conditions studied

- Ovarian Sex-cord Stromal Tumor

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT01770301
- **Lead sponsor:** ARCAGY/ GINECO GROUP
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02
- **Primary completion:** 2017-12
- **Final completion:** 2021-04
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2021-07-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01770301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01770301, "Efficacy and Safety of Bevacizumab (Avastin®) Combined to Weekly Paclitaxel Followed by Bevacizumab (Avastin®) Alone in Patients With Relapsed Ovarian Sex-cord Stromal Tumours (ALIENOR)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01770301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*